<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499612</url>
  </required_header>
  <id_info>
    <org_study_id>05/290120</org_study_id>
    <nct_id>NCT04499612</nct_id>
  </id_info>
  <brief_title>Influence of Cardiac Implantable Electronic Devices on the Hemostatic System</brief_title>
  <official_title>Assessment of the Hemostatic System, Thromboembolic Complications and Cardiovascular Events in Patients With Cardiovascular Implantable Electronic Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ryazan State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ryazan State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hemostasis system is one of the many biological systems of the human body, designed to&#xD;
      preserve the liquid state of blood and prevent its loss during vascular injuries. The ideal&#xD;
      balance between its coagulant and anticoagulant components never occurs. In various diseases&#xD;
      and pathological conditions, the balance of the hemostasis system may be disturbed. Shifts&#xD;
      towards hypercoagulability lead to the development of hemorrhagic complications, opposite&#xD;
      shifts lead to the development of thrombotic complications.&#xD;
&#xD;
      Patients with cardiac implantable electronic devices (CIED) are not rare and unique, today&#xD;
      doctors meet with them every day. Its more than 1.5 million CIED's implanted every year.&#xD;
&#xD;
      Before surgery these patients are standard cardiology department patients with chronic heart&#xD;
      failure (CHF), which develops due to the presence of arrhythmias, coronary heart disease,&#xD;
      hypertension, congenital heart disease, myocardial infarction, myocarditis or other diseases&#xD;
      and conditions. CHF is the most common, severe and unfavorable prognostic complication of&#xD;
      these diseases. With CHF, the balance of the hemostasis system shifts towards&#xD;
      hypercoagulation. Patients with CHF have an increased risk of arterial and venous thrombosis,&#xD;
      pulmonary embolism, myocardial infarction, stroke, numerous brady- and tachyarrhythmias and&#xD;
      other complications.&#xD;
&#xD;
      After CIED implantation, bradyarrhythmia is eliminated, as one of the parts in the&#xD;
      pathogenesis of CHF. Patients, especially those with severe symptoms, improve their condition&#xD;
      in the early postoperative period. In the long-term period, pacing, on the contrary, may&#xD;
      contribute to the progression of CHF. The wrong choice of pacing mode or the place of&#xD;
      electrode implantation can lead to desynchronization of the heart chambers, myocardial&#xD;
      remodeling and left ventricular dysfunction.&#xD;
&#xD;
      Uncertainty is also observed in relation to the hemostasis system after CIED implantation. On&#xD;
      the one hand, correction of bradyarrhythmia and CHF should provide patients with a shift&#xD;
      towards hypocoagulability by normalizing the heart rate. On the other hand, trauma to the&#xD;
      vessel wall during surgery, further placement of the CIED leads in the vessels, and&#xD;
      perioperative stress can lead to even greater shifts towards hypercoagulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      250 patients of similar age, gender, and ethnicity will be divided into five groups: Group&#xD;
      A1-3: 150 patients with indications for cardiac implantable electronic device (CIED)&#xD;
      implantation; Group B: 50 patients with an CIED implanted 8-10 years ago; Group C: 50&#xD;
      patients with diseases similar to group A, but without indications for CIED implantation;&#xD;
      Patients will be followed up for 2 years. Patients of group A1-3 will be taken peripheral&#xD;
      venous blood to assess the studied parameters of hemostasis (platelet count, plateletcrit,&#xD;
      mean platelet volume, platelet distribution width, von Willebrand factor, P-selectin,&#xD;
      coagulation factor I (FI), coagulation factor II (FII), coagulation factor V (FV),&#xD;
      coagulation factor VII (FVII), coagulation factor X (FX), coagulation factor VIII (FVIII),&#xD;
      coagulation factor IX (FIX), coagulation factor XI (FXI), coagulation factor XII (FXII),&#xD;
      plasminogen, soluble fibrin, plasminogen activator inhibitor-1 (PAI-1), D-dimer, antithrombin&#xD;
      III, protein C) and duplex ultrasound of the vessels of the upper and lower extremities&#xD;
      before the operation, after 7 days, 1 and 12 months after the operation. Similar procedures&#xD;
      will be performed for patients of groups B and C only when included in the study.&#xD;
      Echocardiography will be performed on all patients at enrollment, after 12 and 24 months of&#xD;
      follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of thromboembolism: venous thrombosis, pulmonary embolism, arterial thrombosis, arterial thromboembolism, transient ischemic attack, stroke.</measure>
    <time_frame>Up to 2 years after enrollment (according to the study design).</time_frame>
    <description>Development of thromboembolic complications after the cardiac implantable electronic device implantation/replace or thromboembolism in conservative group patients during observation period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of cardiovascular event: myocardial infarction, acute coronary syndrome, atrial fibrillation, decompensation of chronic heart failure.</measure>
    <time_frame>Up to 2 years after enrollment (according to the study design).</time_frame>
    <description>Development of cardiovascular events after the cardiac implantable electronic device implantation/replace or in conservative group patients during observation period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemostasis system markers deviations.</measure>
    <time_frame>Up to 2 years after enrollment (according to the study design).</time_frame>
    <description>Deviation of investigated markers of the hemostasis system from normal values.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Thromboembolism</condition>
  <condition>Cardiac Event</condition>
  <condition>Hemostatic Disorder</condition>
  <arm_group>
    <arm_group_label>Group &quot;Single-chamber CIED&quot; (A1)</arm_group_label>
    <description>50 patients with permanent atrial fibrillation and indications for cardiac implantable electronic device implantation (single-chamber system).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group &quot;Dual-chamber CIED&quot; (A2)</arm_group_label>
    <description>50 patients with atrioventricular block/sick sinus syndrome and indications for cardiac implantable electronic device implantation (dual-chamber system).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group &quot;Dual-chamber CIED + Atrial fibrillation&quot; (A3)</arm_group_label>
    <description>50 patients with atrioventricular block/sick sinus syndrome, paroxysmal or persistent atrial fibrillation and indications for cardiac implantable electronic device implantation (dual-chamber system).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group &quot;CIED Replace&quot; (B)</arm_group_label>
    <description>50 patients with cardiac implantable electronic device implantation 6-12 years ago (single- or dual-chamber system).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group &quot;Conservative&quot; (C)</arm_group_label>
    <description>50 patients with atrioventricular block/sick sinus syndrome/atrial fibrillation and without indications for cardiac implantable electronic device implantation (conservative group).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac implantable electronic device implantation.</intervention_name>
    <description>Patients who have indications will receive cardiac implantable electronic device implantation.</description>
    <arm_group_label>Group &quot;Dual-chamber CIED + Atrial fibrillation&quot; (A3)</arm_group_label>
    <arm_group_label>Group &quot;Dual-chamber CIED&quot; (A2)</arm_group_label>
    <arm_group_label>Group &quot;Single-chamber CIED&quot; (A1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac implantable electronic device replace.</intervention_name>
    <description>Patients who have indications will receive cardiac implantable electronic device replace.</description>
    <arm_group_label>Group &quot;CIED Replace&quot; (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Duplex ultrasound.</intervention_name>
    <description>Patients will undergo ultrasound examination of the vessels of the upper and lower extremities.</description>
    <arm_group_label>Group &quot;CIED Replace&quot; (B)</arm_group_label>
    <arm_group_label>Group &quot;Conservative&quot; (C)</arm_group_label>
    <arm_group_label>Group &quot;Dual-chamber CIED + Atrial fibrillation&quot; (A3)</arm_group_label>
    <arm_group_label>Group &quot;Dual-chamber CIED&quot; (A2)</arm_group_label>
    <arm_group_label>Group &quot;Single-chamber CIED&quot; (A1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography.</intervention_name>
    <description>Patients will undergo an ultrasound examination of the heart.</description>
    <arm_group_label>Group &quot;CIED Replace&quot; (B)</arm_group_label>
    <arm_group_label>Group &quot;Conservative&quot; (C)</arm_group_label>
    <arm_group_label>Group &quot;Dual-chamber CIED + Atrial fibrillation&quot; (A3)</arm_group_label>
    <arm_group_label>Group &quot;Dual-chamber CIED&quot; (A2)</arm_group_label>
    <arm_group_label>Group &quot;Single-chamber CIED&quot; (A1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sampling.</intervention_name>
    <description>Patients will be taken venous blood to determine the studied markers of hemostasis system.</description>
    <arm_group_label>Group &quot;CIED Replace&quot; (B)</arm_group_label>
    <arm_group_label>Group &quot;Conservative&quot; (C)</arm_group_label>
    <arm_group_label>Group &quot;Dual-chamber CIED + Atrial fibrillation&quot; (A3)</arm_group_label>
    <arm_group_label>Group &quot;Dual-chamber CIED&quot; (A2)</arm_group_label>
    <arm_group_label>Group &quot;Single-chamber CIED&quot; (A1)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing treatment in cardiology and cardiac surgery departments who have an&#xD;
        implanted cardiac implantable electronic device or have indication/no indication for&#xD;
        cardiac implantable electronic device implantation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  for group A1-3: atrioventricular block/sick sinus syndrome/atrial fibrillation with&#xD;
             impaired conduction as indications for cardiac implantable electronic device&#xD;
             implantation;&#xD;
&#xD;
          -  for group B: atrioventricular block/sick sinus syndrome/atrial fibrillation with&#xD;
             impaired conduction and cardiac implantable electronic device implanted 6-12 years&#xD;
             ago;&#xD;
&#xD;
          -  for group C: atrioventricular block/sick sinus syndrome/atrial fibrillation with&#xD;
             impaired conduction without indications for cardiac implantable electronic device&#xD;
             implantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active cancer or a remission period of less than 5 years;&#xD;
&#xD;
          -  decompensated somatic pathology;&#xD;
&#xD;
          -  pregnancy or breastfeeding in women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor A. Suchkov, MD, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ryazan State Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladislav O. Povarov, MD, PhD</last_name>
    <phone>+7-915-602-7478</phone>
    <email>povarov.vladislav@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Igor A. Suchkov, MD, DSc</last_name>
    <phone>+7-903-836-2417</phone>
    <email>suchkov_med@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ryazan State Medical University</name>
      <address>
        <city>Ryazan'</city>
        <state>Ryazan</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor A. Suchkov, MD, DSc</last_name>
      <phone>+7-903-836-2417</phone>
      <email>suchkov_med@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Vladislav O. Povarov, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Kalinin RE, Suchkov IA, Shitov II, Mzhavanadze ND, Povarov VO. [Venous thromboembolic complications in patients with cardiovascular implantable electronic devices]. Angiol Sosud Khir. 2017;23(4):69-74. Russian.</citation>
    <PMID>29240058</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac implantable electronic devices</keyword>
  <keyword>Pacing</keyword>
  <keyword>Hemostasis</keyword>
  <keyword>Thromboembolism</keyword>
  <keyword>Cardiovascular events</keyword>
  <keyword>Arrhythmias</keyword>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Chronic heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Basic demographic data, including sex, age, and ethnicity are to be shared if allowed by the privacy policy.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

